Previous Close | 0.6327 |
Open | 0.6800 |
Bid | 0.6100 x 1400 |
Ask | 0.6900 x 1000 |
Day's Range | 0.6200 - 0.6900 |
52 Week Range | 0.6020 - 3.1700 |
Volume | |
Avg. Volume | 246,261 |
Market Cap | 37.651M |
Beta (5Y Monthly) | 1.64 |
PE Ratio (TTM) | 0.40 |
EPS (TTM) | 1.5660 |
Earnings Date | May 08, 2023 - May 12, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.40 |
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will present a poster highlighting new preclinical data for SRF114, the company’s fully human, afucosylated anti-CCR8 antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14-19, 2023, in Orlando, Fl. Details on the p
Surface Oncology ( NASDAQ:SURF ) Full Year 2022 Results Key Financial Results Revenue: US$30.0m (up by US$27.3m from FY...
SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8 antibody, in patients with advanced solid tumors Cash runway guidance extended into the third quarter of 2024 CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor micro